Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Gazprom, Saturn Oil & Gas, Shell - Winners of a supply chain law

In recent weeks, the German media have frequently reported on a so-called supply chain law. The aim of such a law is to ensure that German companies respect human rights and protect the environment in the procurement of materials and products. The world should become a bette...
Mario Hose | July 21, 2020 |

Feb 28th 2020, Silver Chartbook – The weakest link

The weakest link The weakest link is you . That is not always easy to admit, but it is factual, that the main cause for large draw downs is human error. The list of errors in market participation is long. For example running stops or sitting frozen behind the monitor ...
Korbinian Koller | February 28, 2020 |

Mar 7th 2020, Silver Chartbook – Back to basics

Back to basics As extraordinary events happen in global markets right now, conflicting fundamental data can be hard to decipher. We had pandemics before. 1889 Russian flu pandemic, 1918 Spanish flue pandemic. 1957 Asian Flue Pandemic, 1968 Hong Kong flue pandemic and ...
Korbinian Koller | March 9, 2020 |

April 28th 2020, Crypto Chartbook: Uncertainty – Who will win ?

Uncertainty – Who will win? Wouldn’t we all like to know? Fact is that nobody knows. The best a market player can do is an educated guess. Stack your odds diligently and never bet the farm. Let’s take a look at some major market players. Mi...
Korbinian Koller | April 28, 2020 |

NEL ASA, PowerCell Sweden, Royal Helium - aviation as a growth market

The British company Hybrid Air Vehicles is based in Bedford, north of London, and is developing Airlander, the largest aircraft in the world. The special feature of this type, however, is that it is a hybrid of airship and aircraft. Helium keeps the airship in the air and engi...
Mario Hose | August 27, 2020 |

Why Provention Bio Is in My Portfolio

Quite often when I write about companies I'm just about the only one doing so. It's in these situations that Tailwinds can add value by not only highlighting our investment thesis, but in educating investors about a company for which there is little to no publicly avail...
Streetwise Reports | August 26, 2019 |

The Impossible Recession in the World’s Playground

Over the last six months, it has become very apparent that our global economy is changing. Yet most investors seem entirely complacent. FTD’s ™, aka Financially Transmitted Diseases , will start to appear and be used more frequently. And the policym...
Marin Katusa | September 6, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...
Streetwise Reports | January 6, 2020 |
1 2 3 4 5 6 7